...
ABVXMID

Abivax S.A.

HealthcareBiotechnology
$121.28
$0.02(+1.52%)
52W$4.77
$148.83
FinancialsValuationvs ARGX
Updated Mar 2, 12:00 AM
RSI45
RS Rating98/99
Beta1.07
Volatility68%
F-Score4/9
Mkt Cap$9.6B
EMERGING TREND

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

EMERGING TREND

Abivax S.A. shows underlying uptrend characteristics but has temporarily lost support at the 50-day moving average. Relative strength is leading (RS Rating: 98), indicating clear outperformance against the broad market. Earnings contraction of 145% provides fundamental context to the price action. Investors should exercise caution due to high volatility (68% annualized), which requires wider risk management.

Relative Strength
98
out of 99
Market Leader
Trend Score
3/4
Minervini Criteria
EMERGING TREND
Risk (Beta)
1.07
vs S&P 500
MARKET
52W Position
81%
from 52W low
Near High
Trend & Momentum Analysis

Trend Template (Minervini)

EMERGING TREND3/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$122.97
50 SMA > 100 SMA$114.87
100 SMA > 150 SMA$102.73
150 SMA > 200 SMA$79.80

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$121.40-0.10%BELOW
50 SMA$122.97-1.38%BELOW
100 SMA$114.87+5.58%ABOVE
150 SMA$102.73+18.06%ABOVE
200 SMA$79.80+51.98%ABOVE

Price Performance

1D+1.5%
1W-8.8%
1M+6.4%
3M-2.8%
6M+48.6%
YTD-9.3%
1Y+14.8%
3Y+144.5%
52-Week Trading Range81% from low
$121.28
52W Low$4.77
52W High$148.83

Technical Indicators

RSI (14)NEUTRAL
45.5
305070
VCP ScoreCOOL
6/10
Base depth: 34.1%

Risk Profile

Beta
1.07
52W Vol
68%
ATR
$4.91
Max DD (1Y)
-38%

Volume Analysis

Today
121
50D Avg
1.23M
Vol Ratio
0.00x
Liquidity
LIQUID

Earnings Momentum

Q4'23-34%
$-1.98
Q2'24+63%
$-0.65
Q4'24+17%
$-1.50
Q2'25-10%
$-1.59
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:+94.40%
5 Years:+457.72%
3 Years:+5.63%
TTM:+125.09%

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:+12.00%

Stock Price CAGR

10 Years:+30.76%
5 Years:+70.98%
3 Years:+144.48%
1 Year:+14.79%

Return on Equity

10Y Avg:-128.8%
5Y Avg:-212.1%
3Y Avg:-220.4%
Last Year:-149.0%

Key Metrics

Market Cap$9.6B
Gross Margin1.0%
Net Margin-16.3%
Piotroski F-Score4/9

More ABVX Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

ABVX vs ARGXARGXCANFAKTXRAPT

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 98 meansABVX outperformed 98% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 1.07 means 7% more volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 4/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 6/10 with COOL status.

Frequently Asked Questions

Is ABVX in an uptrend right now?

ABVX has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.

Is ABVX overbought or oversold?

ABVX's RSI (14) is 45. The stock is in neutral territory, neither overbought nor oversold.

Is ABVX outperforming the market?

ABVX has a Relative Strength (RS) Rating of 98 out of 99. Yes, ABVX is a market leader, outperforming 98% of all stocks over the past 12 months.

Where is ABVX in its 52-week range?

ABVX is trading at $121.28, which is 81% of its 52-week high ($148.83) and 81% above its 52-week low ($4.77).

How volatile is ABVX?

ABVX has a Beta of 1.07 and 52-week volatility of 68%. It's more volatile than the S&P 500 - expect bigger swings.